Medtech M&A Activity Is Rising, But Is It Really a Boom?

Over the past several weeks, acquisition announcements have arrived at a rapid pace across the industry. Between transactions involving Medtronic, ResMed, Artivion, and Roche, nearly $2 billion in deal value has been announced in a short period of time.

The headlines naturally raise a question: are we witnessing a true surge in medtech M&A, or are a handful of high-profile deals creating that impression?

A review of recent transactions, combined with activity tracked in Compass AI, suggests that strategic buyers remain highly active. However, the broader data indicate a market that is accelerating within an established trend rather than entering entirely new territory.

The Same Acquisition Playbook Continues to Win

Although the companies and technologies differ, the latest transactions share several common characteristics.

Strategic acquirers continue to target businesses with commercial traction, attractive growth profiles, and technologies that strengthen existing franchises. Rather than transformational platform shifts, most acquisitions remain focused additions that expand already successful business lines.

That pattern is evident across all four recently announced deals.

ResMed Acquires Noctrix Health for $340 Million

ResMed’s planned acquisition of Noctrix Health stands out because of how closely the company fits within ResMed’s existing sleep ecosystem.

Noctrix developed Nidra, a wearable neurostimulation therapy designed for patients suffering from drug-refractory restless leg syndrome (RLS). The condition affects nearly 10% of adults worldwide and shares significant overlap with obstructive sleep apnea, ResMed’s core market. Estimates suggest that 10% to 30% of RLS patients also experience OSA.

From a strategic perspective, ResMed already understands the physician audience, patient population, and distribution channels involved. The company also noted that Noctrix is growing faster and generating stronger gross margins than ResMed itself.

The transaction additionally broadens ResMed’s sleep portfolio while providing exposure to an area that is less directly tied to ongoing discussions around GLP-1 therapies and their potential effect on OSA.

Artivion Moves Quickly on Endospan

Artivion’s $175 million acquisition of Endospan came shortly after FDA approval of the NEXUS Aortic Arch System.

The deal structure may be as noteworthy as the technology itself. According to SEC filings, Artivion previously paid $1 million for an option to acquire Endospan, with the option becoming exercisable following FDA approval of NEXUS. Approval arrived on April 2, 2026, and Artivion exercised the option just over a month later.

The acquisition gives Artivion a comprehensive portfolio of aortic arch solutions and strengthens its competitive position against companies including Cook, Gore, and Terumo.

While the U.S. patient population is relatively limited at roughly 15,000 annually, Artivion appears to be betting on both limited competition and the potential for additional regulatory approvals within Endospan’s broader pipeline.

Roche Expands Its Digital Pathology Strategy with PathAI

Roche announced plans to acquire PathAI in a transaction valued at up to $1 billion, extending a partnership that began in 2021.

PathAI's AISight is a cloud-native image management system that converts physical slide workflows into fully digital, AI-augmented processes. The company’s technology has already gained validation beyond Roche through partnerships with both Quest Diagnostics and Labcorp.

The acquisition supports Roche’s broader strategy of integrating diagnostics, software, and AI capabilities into a unified ecosystem. By combining imaging infrastructure, workflow software, and artificial intelligence under a single platform, Roche hopes to simplify adoption of digital pathology while strengthening biomarker discovery and companion diagnostics development.

Investors and analysts have largely viewed the rationale favorably. The long-term success of the deal will depend in part on how laboratories respond to a more integrated approach.

Medtronic Expands Pain Portfolio with SPR Therapeutics

Medtronic’s planned $650 million acquisition of SPR Therapeutics reflects another familiar theme: buying commercial-stage assets that provide access to attractive growth markets.

SPR’s SPRINT peripheral nerve stimulation system differs from traditional implanted neurostimulation therapies because it is temporary rather than permanent. That distinction allows physicians to intervene earlier in the treatment pathway before considering longer-term implant solutions.

The company brings significant commercial validation, with more than 50,000 implants placed since receiving FDA clearance in 2018.

The timing is notable as well. Just months earlier, Boston Scientific announced its acquisition of Nalu Medical, another peripheral nerve stimulation company. Together, the two transactions suggest increasing competitive interest in the category and highlight the value strategics place on established commercial assets.

What the Data Says About Deal Activity

Despite the recent wave of announcements, Compass AI data suggests overall first-half acquisition activity has remained relatively consistent since 2024.

What stands out is Q2 2026 specifically. April alone produced 10 announced deals, the highest monthly total within the period analyzed. With one month remaining in the quarter, Q2 2026 is on pace to become the most active quarter in the two-year dataset.

That does not necessarily justify calling the current environment an acquisition boom. However, it does reinforce what industry leaders have been signaling publicly. Companies have capital available, strategic priorities remain focused on acquisitions, and there is a growing pool of cleared and commercialized assets available for purchase.

The latest transactions ultimately reinforce the prevailing theme across medtech M&A today: strategics continue to favor proven products, focused portfolio expansion, and acquisitions that complement existing growth engines rather than redefine them.